Urtė Fultinavičiūtė, Author at Clinical Trials Arena

2023 in review: Are clinical trial sponsors and regulators in sync?

Urtė Fultinavičiūtė — Tue, 19 Dec 2023 10:00:00 +0000

Decentralisation, diversity, new trial systems and transparency rules made a mark in 2023, but increasing pressure on sponsors may backfire.

The post 2023 in review: Are clinical trial sponsors and regulators in sync? appeared first on Clinical Trials Arena.

Diversity and ePROs: Still siloed concepts in the era of DCTs?

Urtė Fultinavičiūtė — Thu, 14 Dec 2023 10:00:00 +0000

Low diversity data reporting rates in DCTs using ePROs point to missed opportunities to embrace patient preferences and racial backgrounds.

The post Diversity and ePROs: Still siloed concepts in the era of DCTs? appeared first on Clinical Trials Arena.

Delpor on track with schizophrenia implant late-stage trials

Urtė Fultinavičiūtė — Thu, 07 Dec 2023 10:21:40 +0000

The company plans to conduct several trials with its drug-device combo in schizophrenia and opioid use disorder over the next couple of years.

The post Delpor on track with schizophrenia implant late-stage trials appeared first on Clinical Trials Arena.

Viriom outlines plans for upcoming infectious disease trials

Urtė Fultinavičiūtė — Tue, 05 Dec 2023 09:34:39 +0000

Viriom will initiate two Australia-based Phase I trials investigating its assets in influenza and Covid-19 in 2024, which may lead to studies in the US.

The post Viriom outlines plans for upcoming infectious disease trials appeared first on Clinical Trials Arena.

4Moving Biotech shares innovative trial plans for GLP-1 osteoarthritis drug

Urtė Fultinavičiūtė — Thu, 30 Nov 2023 09:41:10 +0000

4Moving Biotech will use different endpoints and an in-silico add-on trial to investigate 4P004 in the upcoming Phase IIb trial.

The post 4Moving Biotech shares innovative trial plans for GLP-1 osteoarthritis drug appeared first on Clinical Trials Arena.

BerGenBio to power ongoing NSCLC trial with synthetic control arm

Urtė Fultinavičiūtė — Thu, 23 Nov 2023 09:33:09 +0000

BerGenBio plans to initiate the second part of the trial with bemcentinib in early 2024, with initial data expected later in the year.

The post BerGenBio to power ongoing NSCLC trial with synthetic control arm appeared first on Clinical Trials Arena.

Profit vs inquiry: Clash of objectives in academic and commercial trials

Urtė Fultinavičiūtė — Thu, 16 Nov 2023 07:00:00 +0000

Clinical Trials Arena explores how post-marketing studies are still led by academia while commercial sponsors spearhead early clinical research.

The post Profit vs inquiry: Clash of objectives in academic and commercial trials appeared first on Clinical Trials Arena.

Q&A: Pharma’s trial diversity goals may not answer health equity problems

Urtė Fultinavičiūtė — Tue, 14 Nov 2023 09:30:00 +0000

Jayasree Iyer, CEO of Access to Medicine Foundation, discusses that while the pharmaceutical industry is more inclusive, more efforts are needed for global health equity reach.

The post Q&A: Pharma’s trial diversity goals may not answer health equity problems appeared first on Clinical Trials Arena.

FT Summit: AI and regulatory changes at the forefront of industry’s mind

Urtė Fultinavičiūtė — Mon, 13 Nov 2023 09:15:00 +0000

At the FT Global Pharma and Biotech Summit in London, various industry players shared their thoughts on technological and regulatory advancements.

The post FT Summit: AI and regulatory changes at the forefront of industry’s mind appeared first on Clinical Trials Arena.

Health equity and trial diversity questions still not answered by pharma

Urtė Fultinavičiūtė — Thu, 09 Nov 2023 13:51:27 +0000

Commercial companies need to build trust and address medicine affordability questions while ensuring clinical trial diversity.

The post Health equity and trial diversity questions still not answered by pharma appeared first on Clinical Trials Arena.